According to ZERO Prostate Cancer, the relative 5-year survival rate for #prostatecancer diagnosed in its earliest stages is nearly 100% while those with advanced or metastatic prostate cancer drops to 32%. Learn more at ZERO Prostate Cancer: bit.ly/3F3leH8

Data presented at the ASTRO Annual Meeting shows that precision medicine navigators increased the rate of genetic testing in black #prostatecancer patients, which can potential to significantly reduce health inequities. Read more at Inside Precision Medicine: bit.ly/3PZ5nQj

ICYMI - Convergent’s CEO Phil Kantoff discusses his background in clinical research and patient care, the challenges of running a business and the promise of #radiopharmaceuticals. Listen on the Founders Keepers Podcast: bit.ly/3wMlAxP #radiopharma #ProstateCancer

This week is #NationalHealthEducationWeek. This week is important for creating awareness of major public health issues and to promote better understanding in health education. #NHEW2023 Learn more: bit.ly/3F2ekko

CEO Dr. Philip Kantoff will be featured in WuXi AppTec’s 4th episode of the “BOLD: Innovation That Matters” online series, set to air on Thursday, October 26. Register here: bit.ly/3QgngZY #TakingBOLDAction

Be sure to listen to Dr. Philip Kantoff’s discussion on Convergent’s approach to #radiopharmaceuticals in WuXi AppTec’s “BOLD: Innovation That Matters” online event today! bit.ly/3sbfLvc #TakingBOLDAction

#ICYMI, Convergent was recently featured in this article in BioPharma Dive which highlighted several companies that are developing #radiopharmaceuticals for #cancer treatment. Read here by Ben Fidler: bit.ly/3KKGox5

Check out this interesting article in U.S. News & World Report highlighting results from a recent study showing how when healthcare access is equal, the race gap in #prostatecancer survival vanishes. Read here: bit.ly/3Sl6kDZ

November is #NationalFamilyCaregiversMonth. Today we would like to recognize and honor all family caregivers that have provided their immense support to help their loved ones in need. #thankyou

Researchers from The ICR discovered that treatment resistance of metastatic castration-resistant #prostatecancer can be reversed in some people by stopping white blood cells from being “hijacked” and can be used in combination with existing therapies. go.nature.com/3Q6qPl5

Thank you Allison DeAngelis for including Convergent in this comprehensive STAT piece mapping out the recent strides in the #radiopharmaceutical space and where it’s heading. Give it a read at: bit.ly/3sP42mj

Convergent would like to wish everyone a warm and wonderful Thanksgiving filled with love, laughter, and delicious food.

Battling #prostatecancer can be incredibly complicated, but there are countless resources out there to assist you. The Urology Care Foundation provides information for those actively managing their urologic health and those ready to make health changes. bit.ly/40WW1bu

This recent article in MedCity News highlights the potential of #radiopharmaceuticals and what it means for future medical care for patients. Read here>bit.ly/3N5SQsl

Convergent announced the appointment of Scott Myers as Chairman of Board of Directors. "Scott brings an enormous amount of experience and expertise as a CEO, board member and chair in numerous life science companies" - Dr. Kantoff, CEO. Read more here: bit.ly/3wHi5vX

We are proud to share our Co-Founder and CEO Dr. Philip Kantoff has been awarded the ASCO Excellence in Teaching Award, underscoring ASCO’s belief that teaching is a vital part of #cancer care and the future of cancer medicine. For more, visit: connection.asco.org/magazine/featu… #ASCO2024

We are proud to announce that the U.S. FDA has cleared our investigational new drug application for CONV01-α, our lead candidate for the treatment of patients with advanced prostate cancer. To read the full announcement, visit: bit.ly/3VJENhb #ProstateCancer #Oncology

Dr. Jones Nauseef, MD PhD, Senior Medical Director at Convergent Therapeutics will present an update on our Actinium-225 PSMA-targeted radioantibody, CONV01-α at the 2024 Targeted Radiopharmaceuticals Summit. For more, visit:bit.ly/3yd5m56 #ProstateCancer #oncology #PSMA

We are excited to head to San Francisco for the 43rd Annual J.P. Morgan Healthcare Conference to share more about CONV01-α and our pipeline of novel α-radioantibodies. We look forward to hearing insights and trends shaping the industry. #JPM2025